{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:22:21Z","timestamp":1787678541696,"version":"build-2784847793"},"reference-count":9,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,12,30]],"date-time":"2013-12-30T00:00:00Z","timestamp":1388361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>A risk associated with the iron chelator deferiprone is the development of neutropenia or agranulocytosis. Accordingly, the product label recommends weekly blood monitoring and immediate interruption of treatment upon detection of an absolute neutrophil count (ANC) &lt;1.5\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L, out of concern that continued therapy might lead to a more severe drop. However, it is uncertain how these recommendations are followed under real\u2010life conditions and, if they are not followed, whether continuation of therapy results in increased incidence of agranulocytosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>This non\u2010interventional surveillance program assessed the monitoring of deferiprone therapy in clinical practice. A total of 294 patients with transfusion\u2010dependent anemias received deferiprone, as monotherapy or with another chelator, for up to 1 year. The participating physicians were not given any instructions about treatment and monitoring beyond being referred to the information in the package insert.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>ANC monitoring was conducted at an average interval of 5\u2009\u00b1\u20094 weeks, and deferiprone was not always interrupted upon detection of neutropenia. One patient (0.3%) experienced agranulocytosis, and nine others (3%) experienced a total of 11 episodes of neutropenia. All neutropenia episodes resolved; median time to resolution was similar whether or not treatment was interrupted; and no case of neutropenia progressed to agranulocytosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These data indicate that less frequent ANC monitoring and continuation of deferiprone therapy during neutropenia are not associated with prolonged neutropenia or with progression to agranulocytosis. Pediatr Blood Cancer 2014;61:879\u2013884. \u00a9 2014 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.24920","type":"journal-article","created":{"date-parts":[[2013,12,30]],"date-time":"2013-12-30T10:25:11Z","timestamp":1388399111000},"page":"879-884","source":"Crossref","is-referenced-by-count":16,"title":["Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis"],"prefix":"10.1002","volume":"61","author":[{"given":"Mohssen","family":"Elalfy","sequence":"first","affiliation":[{"name":"Ain Shams University Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser A.","family":"Wali","sequence":"additional","affiliation":[{"name":"Child Health Sultan Qaboos University Hospital Muscat Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Qari","sequence":"additional","affiliation":[{"name":"Department of Hematology King Abdulaziz University Hospital Jeddah Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazi","family":"Al Damanhouri","sequence":"additional","affiliation":[{"name":"King Abdulaziz University Hospital Jeddah Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Al\u2010Tonbary","sequence":"additional","affiliation":[{"name":"Children's Hospital, Mansoura University Mansoura Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Yazman","sequence":"additional","affiliation":[{"name":"Department of Hematology Nicosia, North Cyprus, Burhan Nalbantoglu State Hospital Nicosia Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakaria","family":"Al Hawsawi","sequence":"additional","affiliation":[{"name":"Ministry of Health Madinah Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"Karakas","sequence":"additional","affiliation":[{"name":"Istanbul University, School of Medicine Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurdanur","family":"Kilinc","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Pediatric Hematology Cukurova University Adana Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Akif","family":"Yesilipek","sequence":"additional","affiliation":[{"name":"Pediatric Hematology Akdeniz University School of Medicine Antalya Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Badr","sequence":"additional","affiliation":[{"name":"Zagazig University Thalassemia Association Zagazig Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usama","family":"Elsafy","sequence":"additional","affiliation":[{"name":"Zagazig University Thalassemia Association Zagazig Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Salama","sequence":"additional","affiliation":[{"name":"Paediatric Haematology Alexandria University Alexandria Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousryeia","family":"Abdel Rahman","sequence":"additional","affiliation":[{"name":"Assuit University Hospital Assuit Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shebl","family":"Shebl","sequence":"additional","affiliation":[{"name":"Pediatric Hematology Unit Tanta University Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Stilman","sequence":"additional","affiliation":[{"name":"ApoPharma Inc. Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Toiber Temin","sequence":"additional","affiliation":[{"name":"ApoPharma Inc. Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Tricta","sequence":"additional","affiliation":[{"name":"ApoPharma Inc. Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,12,30]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000243800"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2948"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2933"},{"key":"e_1_2_6_5_1","first-page":"1","article-title":"Agranulocytosis due to deferiprone: A case report with cytomorphological and functional bone marrow examination","volume":"4","author":"Masera N","year":"2011","journal-title":"Blood Transfus"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01866.x"},{"key":"e_1_2_6_7_1","unstructured":"Food and Drug Administration Oncologic Drugs Advisory Committee (ODAC) Briefing Document NDA # 21\u2010825 Ferriprox\u00ae (deferiprone).http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/drugs\/OncologicDrugsAdvisoryCommittee\/ucm271538.pdf"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-7-200704030-00004"},{"key":"e_1_2_6_9_1","first-page":"275","article-title":"Agranulocytosis in beta thalassemia major patients treated with oral iron chelating agent (deferiprone)","volume":"23","author":"Wali Y","year":"2008","journal-title":"Oman Med J"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181ec0f13"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24920","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.24920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T14:27:27Z","timestamp":1696516047000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.24920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,30]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1002\/pbc.24920"],"URL":"https:\/\/doi.org\/10.1002\/pbc.24920","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,30]]}}}